Company news
Santen Pharmaceutical Co., Ltd. (TSE:4536) news
Santen Pharmaceutical Co., Ltd. news releases on 6ix. Latest, Sep 30, 2026: Notice on the Completion of Disposal of Treasury Shares for the Post-delivery Type…
Press releases & updates
Notice on the Completion of Disposal of Treasury Shares for the Post-delivery Type Performance-Linked Stock Remuneration Plan
September 30, 2026
Santen Pharmaceutical : New Drug Application Filing Accepted for Review in China for STN1012700 (Atropine Sulfate Ophthalmic Solution 0.025%), an Ophthalmic Solution to Slow the Progression of Myopia
September 14, 2026
Notice on the Disposal of Treasury Shares for the Post-delivery Type Performance-Linked Stock Remuneration Plan
September 3, 2026
Summary of Consolidated Financial Results for the Three Months Ended June 30, 2026 (IFRS)
August 6, 2026
Teijin Receives Approval for Additional Indications of XEOMIN® for Cervical Dystonia and Blepharospasm in Japan
June 19, 2026
Santen Pharmaceutical : China Signs Exclusive Distribution and Promotion Agreement for Five Marketed Glaucoma Eyedrops Products in the Chinese Mainland
April 16, 2026
Santen Pharmaceutical : Notice of Board of Director and Corporate Auditor Nominations
March 19, 2026
RVL Pharmaceuticals Announces Santen Obtains Manufacturing and Marketing Approval in Japan for UPNEEQ® Mini Ophthalmic Solution 0.1%
January 8, 2026
Santen Pharmaceutical : Launches Verkazia® (Ciclosporin Eye Drops (III) ) in China For the Treatment of Severe Vernal Keratoconjunctivitis (VKC) in Children and Young Adults
December 23, 2025
Santen Pharmaceutical : Obtains Manufacturing and Marketing Approval in Japan for UPNEEQ® Mini Ophthalmic Solution 0.1%, a Treatment for Acquired Blepharoptosis
December 22, 2025
Santen Pharmaceutical : Aflibercept intraocular injection kit 40 mg/mL Bayer Listed in NHI Drug Price List
December 5, 2025
Santen Pharmaceutical : and SERI Collaborate to Advance Disease-Modifying Therapies for Major Eye Diseases
December 3, 2025
Santen Pharmaceutical : On December 1, Resumption of Shipments for Dry Eye Treatment “DIQUAS LX Ophthalmic Solution 3%”
November 20, 2025
Santen Pharmaceutical : Announces Completion of Share Buyback
November 6, 2025
Santen Pharmaceutical : Announces Cancellation of Treasury Shares
November 6, 2025
Santen Pharmaceutical : Summary of Consolidated Financial Results for the Six Months Ended September 30, 2025 (IFRS)
November 6, 2025
Santen Pharmaceutical : Announces Status of Share Buyback
November 4, 2025
Santen Pharmaceutical : Launches SETANEO® Ophthalmic Solution 0.002% in Japan for the Treatment of Glaucoma and Ocular Hypertension
October 22, 2025
Santen Pharmaceutical : Korea Signs an Exclusive Promotion and Distribution Agreement for VEGF Inhibitors Beovu® and Lucentis® in the Republic of Korea
October 19, 2025
Santen Pharmaceutical : Announcement Regarding the Resumption of Shipments for Dry Eye Treatment “DIQUAS LX Ophthalmic Solution 3%”
October 16, 2025
Koya Medical Honored by Goldman Sachs for Entrepreneurship
October 15, 2025
Santen Pharmaceutical : Notice on the Disposal of Treasury Shares for the Post-delivery Type Performance-Linked Stock Remuneration Plan
October 1, 2025
Santen Pharmaceutical : and RemeGen Announce Biologic License Application (BLA) Acceptance for RC28-E Intravitreal Injection in Diabetic Macular Edema in China
September 30, 2025
Santen Pharmaceutical : Publishes its Annual Integrated Report “ Report 2025”
September 25, 2025
Santen Pharmaceutical : Launches TAPCOM® in China for Patients with Open-Angle Glaucoma or Ocular Hypertension
August 31, 2025
Santen Pharmaceutical : Obtains Manufacturing and Marketing Approval in Japan for SETANEO® 0.002% Ophthalmic Solution, a Bicyclic Prostaglandin Derivative that Acts on FP and EP3 Receptors, for Treatment of Glaucoma and Ocular Hypertension
August 25, 2025
RemeGen and Santen Enter into Exclusive Licensing Agreement for Ophthalmic Innovative Drug RC28-E in Greater China and Asian countries
August 18, 2025
Santen Pharmaceutical : Summary of Consolidated Financial Results for the Three Months Ended June 30, 2025 (IFRS)
August 7, 2025